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Native aortic valve thrombosis in primary antiphospholipid syndrome (APLS) is a rare 
entity. We describe a 38-year-old man who presented with neurological symptoms and a 
cardiac murmur. Transthoracic echocardiography detected a large bicuspid aortic valve 
thrombus. Laboratory evaluation showed the presence of antiphospholipid antibodies. 
Anticoagulation was started, and serial echocardiographic studies showed complete 
resolution of the aortic valve vegetation after 4 months. The patient improved clinically 
and had no residual symptoms. This report and review of the literature suggests that 
vegetations in APLS can be treated successfully with conservative treatment, regardless 
of their size.
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INtRoDUCtIoN
Antiphospholipid syndrome (APLS) is a systemic autoimmune disorder characterized by the pres-
ence of antiphospholipid antibodies (aPLs) and clinical features, mainly arterial and/or venous 
thrombosis and/or fetal loss. APLS can be classified as primary in the absence of another autoim-
mune disease, or as secondary in the presence of an underlying disorder, most commonly systemic 
lupus erythematosus. aPLs have been found in around 5% of the general population (1); however, 
only a small proportion will develop APLS. APLS has been estimated to have an incidence of 5 new 
cases per 100,000 people per year, and a prevalence of 40–50 cases per 100,000 people per year (2). 
According to the Sydney criteria (3), APLS is diagnosed based on the presence of at least one clinical 
event (either a vascular thrombosis and/or adverse obstetric event), and the presence of aPL [either 
anticardiolipin (aCL), lupus anticoagulant (LA), or anti-β2 glycoprotein-1 (anti-β2GP1)] on two or 
more occasions, with a minimum 12-week interval. Several clinical features associated with APLS 
have not been included in the Sydney criteria (3). These features include aPL-associated cardiac valve 
disease (ACVD), nephropathy, livedo reticularis, and thrombocytopenia.
Antiphospholipid syndrome significantly impacts the cardiovascular system. ACVD, presenting 
with a valvular mass and/or valvular thickening, is often encountered in APLS. Approximately one-
third of patients with primary APLS exhibit ACVD (4). The most commonly affected valve is the 
mitral valve, followed by the aortic valve (5), with regurgitation being the most common functional 
abnormality (6). These valvular lesions are usually of minor hemodynamic significance, but have 
been associated with serious thromboembolic events.
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There is no general consensus on the definitive treatment of 
ACVD. Popular regimens used for the treatment of ACVD include 
the following: warfarin, antiplatelet agents, and low-molecular-
weight heparin (LMWH). The efficacy of anticoagulant therapy 
on valvular masses is controversial. Some believe that ACVD 
valvular masses are due to inflammation and thus anticoagula-
tion would be ineffective (7), whereas others were successful with 
anticoagulation in the treatment of these lesions (8). A small 
minority of APLS patients (4–6%) develop a valve disease that is 
severe enough to require valvular surgery (9). However, surgical 
patients had a higher rate of complications, mostly bleeding and 
thrombosis (10).
Bicuspid aortic valve (BAV) is the most common congenital 
heart disease, affecting 1–2% of the population with a higher 
prevalence (2:1) in males (11). Individuals with BAV have a 
potential risk of complications; the most commonly being 
aortic stenosis, aortic regurgitation, aortic dissection, and 
infective endocarditis (IE). Aortic valve thrombosis in the 
setting of BAV is a rare complication, and only few cases have 
been reported (12).
To the best of our knowledge, complete resolution of a large 
bicuspid aortic mass with anticoagulation in the setting of APLS 
has not been reported in the medical literature. Therefore, this 
communication explores this rare phenomenon with a review of 
the literature.
Case RepoRt
A 38-year-old man was referred to us, by his primary care physi-
cian, for evaluation of possible aortic valvulopathy. He is known to 
have dyslipidemia; for which he was not taking any medications. 
He is a heavy smoker (45 pack-year), drinks alcohol occasionally, 
and denies drug-use.
Six months before presentation, he started having short 
episodes (<10  min) of left-arm numbness and weakness with 
headache and dizziness. He also reported having dyspnea upon 
exertion. One month prior to his presentation, the patient was 
hospitalized due to the exacerbation of his clinical symptoms, in 
addition to a 2-h episode of ataxia and diplopia. Initial workup 
included computed tomography (CT) and magnetic resonance 
imaging of the brain, electroencephalogram, and lumbar punc-
ture; all of which were unremarkable. Patient was suspected to 
have simple partial seizure and atypical migraine, and was dis-
charged on carbamazepine and prophylactic propranolol. Upon 
follow up with his primary care physician, the patient’s symptoms 
did not improve and a thorough physical examination revealed a 
cardiac murmur in the aortic region. Based on this new cardiac 
finding, the patient was referred to us for further evaluation and 
management.
Upon presentation to our clinic, he was afebrile and hemo-
dynamically stable. Cardiovascular examination revealed a 
combined systolic–diastolic murmur best heard at the second 
right intercostal space, suggesting aortic valve disease. The rest of 
the physical examination was unremarkable.
An electrocardiogram, done at presentation, revealed left 
ventricular hypertrophy. A transthoracic echocardiogram (TTE) 
showed an irregular ovoid laminated mass, 3.7 cm × 2.1 cm in 
size (Figures 1A,B). The mass was firmly attached to the aortic 
valve surface and exhibited no independent motion. Doppler 
echocardiography revealed Grade II–III aortic regurgitation and 
a mean gradient of 21 mmHg across the aortic valve. There was 
also evidence of moderate left ventricular hypertrophy and dila-
tion with a normal ejection fraction (>55%).
Patient was then admitted to the hospital for further workup 
of his condition. Laboratory studies revealed a normal complete 
blood count, an erythrocyte sedimentation rate of 64 mm/h, a 
C-reactive protein of 20 mg/L, and negative blood cultures (three 
separate sets). Cardiac enzymes were normal and chest radiogra-
phy showed no significant findings.
Hypercoagulability workup was done. It revealed the presence 
of aCL (IgG isotype) in serum with a titer of 205 GPL (normal 
level <  20 GPL) and was positive for LA; anti-β2GP1 was not 
tested for technical reasons. The levels of protein C, protein S, 
factor V Leiden, and homocysteine were normal. Serological 
markers for connective tissue disorders, including antinuclear 
antibodies, rheumatoid factor, anti-neutrophilic–cytoplasmic 
antibodies, anti-double-stranded-DNA antibodies, and anti-
Smith antibodies were all negative. Serologies for hepatitis B, 
C, and HIV were negative. Furthermore, CT scans of the chest, 
abdomen, and pelvis were insignificant.
The diagnosis of non-bacterial thrombotic endocarditis 
(NBTE) in the setting of primary APLS was suspected. The patient 
was started on anticoagulation with LMWH and then bridged 
to oral warfarin; INR 2–3 was maintained. Carbamazepine and 
propranolol were discontinued. The patient was educated about 
the importance of smoking cessation and adherence to his statin 
therapy.
At the 3-month follow-up, only aCL level was repeated and 
was found to be elevated (170 GPL). Serial TTE controls showed 
progressive resolution of the mass, with complete regression 
4  months after therapy (Figures  1C,D). In addition, there was 
regression in the aortic regurgitation to Grade I, and reduction 
in the left ventricular hypertrophy and dilation. Interestingly, 
the resolution of the valvular mass unveiled a BAV that was not 
previously diagnosed (Figure 2).
Furthermore, a cardiac CT was done to rule out APLS-induced 
coronary artery disease; it showed no abnormalities. The patient 
was maintained on warfarin, and subsequent follow-ups showed 
him to be clinically asymptomatic.
DIsCUssIoN
Cerebral involvement is prominent in primary APLS; with stroke 
(19.8%) and transient ischemic attack (TIA) (11.1%) being its 
most common clinical manifestations (13). Hughes et  al. (14) 
reported that in young patients (<45 years), more than 20% of 
strokes are potentially associated with APLS. Recurrent transient 
episodes of visual disturbances, numbness, weakness, and dizzi-
ness can all be expressions of TIA (15). All these were present in 
our patient and might explain his symptoms.
Arterial thrombosis involves the brain vasculature in more 
than 50% of the cases, and it is the main cause of cerebral ischemia 
in primary APLS (16). However, an association has been reported 
between ACVD and central nervous system manifestations of 
FIgURe 2 | Follow-up transthoracic echocardiography performed 5 months 
after presentation, showing the presence of previously undiagnosed bicuspid 
aortic valve.
FIgURe 1 | Transthoracic echocardiography performed at presentation reveals a large ovoid laminated mass on the aortic valve, measuring 3.7 cm × 2.1 cm on 
apical five chamber view (a) and 2.4 cm × 1.6 cm on parasternal short-axis view (B). Follow-up transthoracic echocardiography performed after 4 months of 
anticoagulation shows complete resolution of the valvular mass on apical five-chamber view (C) and parasternal short-axis view (D).
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the syndrome, which suggests that cerebral emboli from non-
infectious valvular lesions, often referred to as NBTE, may be a 
risk factor (17).
Valvular masses have a wide differential diagnosis, which 
includes NBTE, IE, and cardiac tumor. It is clinically challeng-
ing to distinguish between IE and NBTE due to APLS. In fact, 
both share many clinical features including vascular thrombo-
embolic events, valvular vegetations, and renal and cutaneous 
involvement. In addition, fever can be present in APLS, and aPL 
can be frequently found to be temporarily elevated during infec-
tions (18). Our patient did not satisfy the modified Duke criteria 
for IE. Since these criteria are sensitive for disease detection and 
have a high negative predictive value (19, 20), the diagnosis of IE 
was rejected.
Aortic valvular masses also raise the suspicion of cardiac tumor, 
an important differential diagnosis that should not be overlooked. 
The best way to diagnose a cardiac tumor is by excision and histo-
pathologic examination. However, echocardiography can be used 
to distinguish between a tumor and a thrombus based on imaging 
characteristics of the mass. Thrombotic mass is characterized by 
an irregular or lobulated shape, laminated appearance, micro-
cavitations, and absence of a pedicle (21). In contrast, a cardiac 
tumor usually appears as a small, mobile, pedunculated or sessile 
valvular, or endocardial mass (22). In our case, the characteristics 
of the lesion were typical of that of a thrombus.
The Sydney criteria committee proposes a minimal consensus 
concerning valvular lesions in APLS but argues against adoption 
as criteria (3). This consensus defines ACVD as the presence of 
aPL, in addition to echocardiographic detection of a valvular 
lesion and/or dysfunction (regurgitation and/or stenosis of mitral 
and/or aortic valve or any combination of the above) (3). In our 
patient, such features were present and thus swayed our diagnosis 
toward ACVD manifesting as NBTE.
Echocardiography is essential in the diagnosis of ACVD. 
About 30–40% of valvular lesions in the setting of APLS can be 
4Rachwan et al. BAV Thrombus in Primary APLS
Frontiers in Cardiovascular Medicine | www.frontiersin.org September 2017 | Volume 4 | Article 59
detected by TTE, while 60–80% of lesions can be detected by 
transesophageal echocardiography (TEE) (23). TTE can be used 
initially to detect the presence of a cardiac mass. However, if TTE 
results were non-diagnostic or equivocal, TEE would be a more 
accurate modality due to its higher sensitivity and specificity (24).
Native aortic valve thrombosis is a rare event. In ACVD and 
BAV, valvular dysfunction is associated with abnormal blood 
flow, which can induce endothelial lesion and trigger thrombus 
formation (25). Furthermore, coagulopathy in APLS can induce 
aortic valve thrombosis. This is possibly due to particular affinity 
of aPL to valve endothelium that leads to formation of an immune 
complex, which can cause an injury to the endothelium (26). 
Therefore, we cannot be certain about the exact role that each 
of ACVD and BAV played in the pathogenesis of the thrombotic 
mass observed in our case.
In terms of treatment, there have been no set guidelines for the 
definitive treatment of ACVD. Similar to other reports (27–29), 
our case has shown anticoagulation to be effective in treating 
valvular vegetation in primary APLS. The optimal intensity of 
anticoagulation for the prevention of recurrent thrombosis in 
patients with APLS is uncertain. Two randomized controlled 
trials found that high-intensity anticoagulation (INR >  3) was 
not superior to moderate-intensity anticoagulation (INR 2–3) 
in patient with APLS, and was associated with a higher rate of 
bleeding complications (30, 31). Therefore, we suggest the use 
of anticoagulation with an INR target of 2–3 as a standard of 
treatment. In addition, most specialists recommend lifelong use 
of anticoagulation due to the high recurrence rate of thrombotic 
events in APLS (32, 33). Modification of concomitant risk factors 
for thrombosis, such as hypertension, dyslipidemia, and smoking 
cessation, must also be addressed.
In conclusion, our report suggests that conservative treatment 
with anticoagulation along with vigilant observation might be the 
best therapeutic plan for patients with aortic valvular masses in 
the setting of APLS. However, these results should be approached 
with caution as whether conservative management with antico-
agulant or aortic valve replacement ought to be recommended 
remains unresolved due to the rarity of this condition and the 
lack of trial data.
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